Humacyte Inc. Common Stock (HUMA)

About HUMA

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into pati…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

184

Website

humacyte.com/

Fundamentals

1-day range

$0.6401$0.6954

Market cap

$153.04M

P/E (trailing)

—

P/E (forward)

-2.63

EPS (trailing)

$-0.57

Dividend yield

—

Beta

2.53

Avg. volume

11.01M

Forecasts

5 analyst ratings

Humacyte Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• ENGN

  enGene Therapeutics Inc. Common Stock

  $1.83

  ▼ 4.19%
  Market cap $118.57MP/E —
  $1.4$12.25

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Humacyte Confirms Plans For ATEV Supplemental BLA Filing
  benzinga · 8/24/2026
• Humacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons
  Benzinga · 8/18/2026
• Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1
  Benzinga · 8/13/2026
• Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate
  Benzinga · 8/12/2026

• Wallace Max N. · June 11, 2026 · Grant

  80.0K
• Laura E. Niklason · June 11, 2026 · Grant

  80.0K
• Jones Keith Anthony · June 11, 2026 · Grant

  80.0K
• Charles Bruce Green · June 11, 2026 · Grant

  80.0K
• Seimetz Diane · June 11, 2026 · Grant

  80.0K
• Bamforth John Philip · June 11, 2026 · Grant

  80.0K
• Brown Emery N. · June 11, 2026 · Grant

  80.0K
• Brady W. Dougan · June 11, 2026 · Grant

  0
• Michael T. Constantino · June 11, 2026 · Grant

  80.0K
• Windham-Bannister Susan Richards · June 11, 2026 · Grant

  80.0K
• Kathleen Sebelius · June 11, 2026 · Grant

  80.0K
• Kathleen Sebelius · May 19, 2026 · Buy

  56.8K @ $0.88
• Shamik J. Parikh · May 18, 2026 · Sale

  45.9K @ $0.8967
• Dale A. Sander · May 18, 2026 · Sale

  45.9K @ $0.8967
• Michael T. Constantino · May 18, 2026 · Buy

  11.0K @ $0.8945

Institutional Ownership

March 31, 2026

Total shares held

58.25M

Total value held

$35.13M

Institutional holders

156